Icon has gained several new technologies from Proteome Sciences to help it bolster the biomarker work it does for drug developers. "This complements Icon's extensive portfolio of biomarker development and analysis services to help sponsors identify, implement, and interpret the right biomarkers to inform their preclinical and clinical drug development," comments John Allinson, VP biomarker lab services, ICON development solutions. Story